

## Synthesis of 10b-*R*-Hydroxy-pancratistatin via Narciclasine

George R. Pettit,\* Noeleen Melody, Michael O'Sullivan, Michael A. Thompson, Delbert L. Herald and Brian Coates

Cancer Research Institute and Department of Chemistry, Arizona State University, Tempe, Arizona 85287-1604, USA

A diastereoselective synthesis of 10b-*R*-hydroxy-pancratistatin **3** from narciclasine **1** has been achieved.


Traditional medicinal applications recorded over more than a millennium<sup>1b</sup> have been the impetus for many studies of amaryllidaceous plants,<sup>2a-f</sup> resulting in the identification of a large family of structurally related phenanthridone constituents such as narciclasine<sup>2a</sup> **1**, narciprimine,<sup>2b</sup> trans-dihydro-narciclasine,<sup>2c</sup> 7-deoxy-narciclasine,<sup>2d</sup> 7-deoxy-trans-dihydro-narciclasine<sup>2e</sup> and pancratistatin,<sup>1a,2d</sup> **2**. The latter isocarbostyryl was isolated<sup>2d,3</sup> from the bulbs of *Hymenocallis* (formerly *Pancratium*) *littoralis* (Jacq.) native to Hawaii in relatively low (0.0019%) yields, and is undergoing preclinical development as an anticancer<sup>4a</sup> and antiviral drug.<sup>4b,c</sup> Consequently, pancratistatin has become a very important, and surprisingly difficult, synthetic target.<sup>5</sup> The six contiguous asymmetric centres in the C-ring of the phenanthridone skeleton adds to the challenge. To date, only one total synthesis of pancratistatin has been reported.<sup>6</sup> Although a considerable achievement, this synthesis only provided racemic pancratistatin in 0.13% overall yield *via* 26 steps. Therefore, isolation from plants still remains the only practical route to the multigram quantities of this valuable compound necessary for eventual clinical trials.

An attractive solution to the preclinical supply problems encountered with pancratistatin would be a high yield partial synthesis from narciclasine **1** already available in multigram quantities from the bulbs of various Amaryllidaceae species. We now report a synthetic approach to pancratistatin **2** starting from narciclasine **1** that has resulted in the synthesis of 10b-*R*-hydroxy-pancratistatin **3**. Narciclasine **1** was isolated in multigram quantities by scale-up isolation from a *Narcissus* *sp.*<sup>4</sup> and allowed to react under the special Sharpless<sup>7</sup> osmium tetroxide conditions to give exclusively the diol derivative **3** (72% yield), Scheme 1. When hydroquinine 4-chlorobenzoate (HQ) was replaced with its diastereoisomer hydroquinidine 4-chlorobenzoate (HQD) diol **3** (dp 269 °C) remained as the only product detected. The stereochemical result corresponds to Kishi's<sup>7</sup> predictions that approach of osmium tetroxide to the face of the olefinic bond is opposite to that of a pre-existing hydroxy group in an allylic alcohol. The presence of either chiral ligand, (HQ or HQD), failed to induce the formation of 10b-*S*-hydroxy-isopancratistatin. Acetylation of narciclasine **1** afforded tetraacetate **4** (80% yield) which when osmlyated (Scheme 1) gave exclusively diol **5** (76% yield). Deacetylation using a methanolic ammonia solution led to alcohol **3**.


Detailed analysis of the NMR 2D COSY, <sup>1</sup>H-<sup>1</sup>H correlation spectrum completed assignment of the hydrogen atom resonances for the 1D NMR spectrum. Both deuterium exchange and highfield (400 MHz) homonuclear decoupling experiments permitted measurement of the coupling constant (*J*<sub>1,2</sub> = 9 Hz) for alcohol **3**. Interpretation of further NMR spectral results suggested introduction of a β-*cis*-diol into the phenanthridone at the 1 and 10b positions. That assumption was confirmed by an X-ray crystal structure determination† of the acetate derivative **5**. A suitable crystal (0.08 × 0.14 × 0.40 mm) was grown from methanol. The structure was solved with the direct methods program SIR88.<sup>8b</sup> All non-hydrogen atoms, with the exception of the aromatic acetate group, were located on the first run of SIR88, using the default settings. Subsequent difference Fourier maps revealed considerable disorder in the region of the phenol acetate at C-7. The disorder was finally resolved by choosing two alternate rotational isomers for the acetate unit (Fig. 1), each of which was assigned 0.50 occupancy. All non-hydrogen atoms were

refined<sup>8a</sup> anisotropically, with the exception of the aromatic acetates which were refined isotropically by full-matrix least squares methods. All hydrogen atom coordinates were calculated at optimum positions and then forced to ride the atoms to which they were attached, but were not refined. The refinement of 322 parameters converged at *R* = 0.0552 for 1690 observed reflections. The largest difference peak and hole in the final difference Fourier were 0.436 and -0.297 e Å<sup>-3</sup> respectively.

The X-ray molecular structure of 10b-*R*-hydroxy-pancratistatin tetraacetate **5** is shown in Fig. 1. The two hydroxy



**Scheme 1** Reagents and conditions: i, acetic anhydride, pyridine, 24 °C; ii, catalytic osmium tetroxide, 4-methylmorpholine-*N*-oxide, hydroquinine 4-chlorobenzoate, 9:1 *v/v* dimethylformamide-H<sub>2</sub>O, 0–24 °C; iii, methylene chloride, 2 mol dm<sup>-3</sup> ammonia in methanol, 24 °C



**Fig. 1** X-ray molecular structure of 2,3,4,7-tetraacetoxy-10b-*R*-hydroxypancratistatin **5** (less H atoms) depicting the two C-7 acetate rotamers

groups in the 1- and 10b-positions are on the  $\beta$ -face. As noted above, the phenol acetate unit attached to C-7 seemed to exhibit considerable disorder. Rather than being coplanar with the aromatic ring as expected it was found to deviate from coplanarity with the aromatic A-ring by  $+18.9^\circ$  and  $-24.7^\circ$ . These two alternate acetate sites exhibit the characteristics of conformational isomers (rotamers) as a result of substantial steric hindrance between the carbonyl oxygen of the acetate and the carbonyl of the lactam on the adjacent B-ring. As a result, two stable rotamers can be envisioned, Fig. 1.

After the large number of attempts to hydroxylate or otherwise selectively oxidize the 1,10b-olefin system, we were pleased to observe the totally diastereoselective osmylation of olefins **1** and **4** to afford alcohols **3** and **5** respectively. Houk has suggested<sup>11</sup> staggered models for the transition state structures, based on *ab initio* calculations, for the reaction of allylic alcohols<sup>10,7</sup> with osmium tetroxide. The allylic groups play decisive roles in obtaining the high degree of stereoselectivity.

Significantly, the cancer cell growth inhibitory activity of 10b-(R)-hydroxy-pancratistatin **3** against the P388 lymphocytic murine leukaemia and a selection of human cancer cell lines was found to be about 1000 times less potent than pancratistatin **2**. Apparently, the added steric features of the 10b- $\beta$ -hydroxy group causes a pronounced reduction in cancer cell growth inhibition.

Presently, we are investigating a number of methods<sup>12</sup> for cleavage of the 10b-benzyl alcohol by hydrogenolysis that will complete this potentially practical synthetic route to pancratistatin. Furthermore, employing narciclasine as a relay would complete a formal total synthesis of pancratistatin. However, the superficially simple final step involving benzyl-oxygen bond cleavage has, to date, proved refractory and will require further extensive study.

Financial assistance from Outstanding Investigator Grant CA 44344-O1A1-05 awarded by the Division of Cancer Treatment, National Cancer Institute, DHHS; the Arizona Disease Control Research Commission; the Robert B. Dalton Endowment Fund; Eleanor W. Libby, the Waddell Foundation (Donald Ware); Virginia Piper; Herbert and Diane Cummings; Polly J. Trautman and Lottie Flugel is acknowledged. We also thank Drs Michael D. Williams, Grazyna Groszek, Jean-Charles Chapuis, Jean M. Schmidt, Fiona Hogan, the US National Science Foundation (Grants CHE-8409644 and BBS-88-04992) and the Midwest Center for Mass Spectrometry, the University of Nebraska-Lincoln (NSF Regional Instrumentation Grants CHE-8620177 and DIR9017262) for assistance.

Received, 6th September 1994; Com. 4/05447D

## Footnote

<sup>†</sup> Crystal data for compound **5**:  $C_{22}H_{23}NO_{13}$ ,  $M = 509.41$ , orthorhombic,  $a = 9.096(1)$ ,  $b = 9.799(2)$ ,  $c = 25.570(5)$  Å,  $V = 2279.10$  Å<sup>3</sup>, space group  $P2_12_12_1$ ,  $D_m = 1.467$  g cm<sup>-3</sup>,  $D_c = 1.485$  g cm<sup>-3</sup>,  $Z = 4$ ,  $F(000) = 1064$ , graphite-monochromated Cu-K $\alpha$  radiation,  $\lambda = 1.54184$  Å,  $\mu = 1.074$  mm<sup>-1</sup>. The intensities of 1891 independent reflections with  $2\theta \leq 120^\circ$  were measured on an Enraf-Nonius CAD4 diffractometer at 26 °C using the  $\omega/2\theta$  scan technique, of which 1690 reflections with  $I > 2\sigma(I_o)$  were used in refinement.<sup>8a</sup> Atomic coordinates, bond lengths and angles, and thermal parameters have been deposited at the Cambridge Crystallographic Data Centre. See Information for Authors, Issue No. 1.

## References

- (a) Antineoplastic agents 321 and for series part 320 refer to: G. R. Pettit, S. Freeman, M. J. Simpson, M. A. Thompson, M. R. Boyd, M. D. Williams, G. R. Pettit III and D. L. Doubek, *Anticancer Drug Design*, in the press; (b) J. B. Gardeil (translator), *Traduction des Oeuvres Medicales d'Hippocrate*, Meilhec et Cie, Toulouse, 4 vols. 1801; (c) J. L. Hartwell, *Lloydia*, 1967, **30**, 379; (d) S. F. Martin, in *The Alkaloids*, ed. A. Brosi, Academic, New York, 1987, vol. 30, pp. 251–376; (e) E. Tojo, *J. Nat. Prod.*, 1991, **54**, 1387; (f) J. Bastida, C. Codina, F. Viladomat, M. Rubiralta, J.-C. Quirion and B. Weniger, *J. Nat. Prod.*, 1992, **55**, 122.
- (a) F. Piozzi, C. Fuganti, R. Mondelli and G. Ceriotti, *Tetrahedron*, 1968, **24**, 1119; (b) T. Okamoto, Y. Torii and Y. Isogai, *Chem. Pharm. Bull.*, 1968, **16**, 1860; (c) A. Mondon and K. Krohn, *Chem. Ber.*, 1975, **108**, 445; (d) G. R. Pettit, V. Gaddamidi, G. M. Cragg, D. L. Herald and Y. Sagawa, *J. Chem. Soc., Chem. Commun.*, 1984, 1693; (e) G. R. Pettit, G. M. Cragg, S. B. Singh, J. A. Duke and D. L. Doubek, *J. Nat. Prod.*, 1990, **53**, 176; (f) G. R. Pettit, G. R. Pettit III, R. A. Backhaus, M. R. Boyd and A. W. Meerow, *J. Nat. Prod.*, 1993, **56**, 1682.
- G. R. Pettit, V. Gaddamidi and G. M. Cragg, *J. Nat. Prod.*, 1984, **47**, 1018.
- (a) G. R. Pettit, V. Gaddamidi, D. L. Herald, S. B. Singh, G. M. Cragg and J. M. Schmidt, *J. Nat. Prod.*, 1986, **46**, 995; (b) B. Gabrielsen, T. P. Monath, J. W. Huggins, D. F. Kefauver, G. R. Pettit, G. Groszek, M. Hollingshead, J. J. Kirsi, W. M. Shannon, E. M. Schubert, J. DaRe, B. Ugarkar, M. A. Ussery and M. J. Phelan, *J. Nat. Prod.*, 1992, **55**, 1569; (c) B. Gabrielsen, T. P. Monath, J. W. Huggins, J. J. Kirsi, M. Hollingshead, W. M. Shannon and G. R. Pettit, *Natural Products as Antiviral Agents*, ed. C. K. Chu and H. G. Cutler, Plenum, New York, 1992, pp. 121–135.
- (a) R. D. Clark and M. Souchet, *Tetrahedron Lett.*, 1990, **31**, 193; (b) R. C. Thompson and J. Kallmerton, *J. Org. Chem.*, 1990, **55**, 6076; (c) N. Chida, M. Ohtsuka and S. Ogawa, *Tetrahedron Lett.*, 1991, **32**, 4525; (d) R. S. C. Lopes, C. C. Lopes and C. H. Heathcock, *Tetrahedron Lett.*, 1992, **33**, 6775; (e) T. Hudlicky and H. F. Olivo, *J. Am. Chem. Soc.*, 1992, **114**, 9694; (f) N. Chida, M. Ohtsuka and S. Ogawa, *J. Org. Chem.*, 1993, **58**, 4441; (g) S. R. Angle and M. S. Louie, *Tetrahedron Lett.*, 1993, **34**, 4751; (h) M. C. McIntosh and S. M. Weinreb, *J. Org. Chem.*, 1993, **58**, 4823.
- S. Danishefsky and J. Y. Lee, *J. Am. Chem. Soc.*, 1989, **111**, 4829.
- K. B. Sharpless, W. Amberg, Y. L. Bennani, G. A. Crispino, J. Hartung, K.-S. Jeong, H.-L. Kwang, K. Morikawa, Z.-M. Wang, D. Xu and X.-L. Wang, *J. Org. Chem.*, 1992, **57**, 2768; Z.-M. Wang, X.-L. Zhang and K. B. Sharpless, *Tetrahedron Lett.*, 1993, **34**, 2267; W. J. Christ, J. K. Cha and Y. Kishi, *Tetrahedron Lett.*, 1983, **24**, 3947.
- (a) G. M. Sheldrick, SHELX-93. Program for the Refinement of Crystal Structures, University of Göttingen, Germany; (b) M. C. Burla, M. Camalli, G. Cascarano, C. Giacovazzo, G. Polidori, R. Spagna and D. Viterbo, *J. Appl. Cryst.*, 1989, **22**, 389.
- D. H. Williams and I. Fleming, in *Spectroscopic Methods in Organic Chemistry*, McGraw-Hill, London, 1989, 4th edn., p. 92.
- J. S. Panek and P. F. Cirillo, *J. Am. Chem. Soc.*, 1990, **112**, 4873 and refs therein. Kishi and coworkers (ref. 3) have shown that chiral allylic alcohols and ethers undergo diastereoselective osmylation reactions preferentially away from the oxygen function. This pattern has been confirmed in conformationally rigid systems, and therefore seems pertinent to the narciclasine I olefin unit.
- K. N. Houk, *Pure Appl. Chem.*, 1983, **55**, 277.
- (a) G. A. Olah and G. K. S. Prakash, *J. Chem. Soc., Chem. Commun.*, 1978, 397; (b) A. M. Khan, F. J. McQuillin and I. Jardine, *Tetrahedron Lett.*, 1966, **7**, 2649; R. H. Crabtree, H. Felkin, T. Khan and G. E. Morris, *J. Organometallic Chem.*, 1979, **168**, 183; (d) S. K. Boyer, J. Bach, J. McKenna and E. Jagdmann, *J. Org. Chem.*, 1985, **50**, 3408; (e) J. Tsuji, I. Shimizu and I. Minami, *Chem. Lett.*, 1984, 1017; (f) S. Hanessian, T. J. Liak and B. Vanasse, *Can. J. Chem.*, 1981, **39**, 396; (g) R. Sala, G. Daria and C. Passarotti, *Tetrahedron Lett.*, 1984, **25**, 4565; (h) M. E. Krafft and W. J. Crooks, *J. Org. Chem.*, 1988, **53**, 432.